Nanoparticles and the blood coagulation system. Part I: Benefits of nanotechnology

Nanomedicine

Volumn 8, Issue 5, 2013, Pages 773-784

  Ilinskaya, Anna N ^a   Dobrovolskaia, Marina A ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

coagulopathy; disseminated intravascular coagulation; endothelial cell; leukocyte; nanoparticle; platelet; procoagulant activity; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT; NANOPARTICLE; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD FLOW; ENDOTHELIUM CELL; HUMAN; IMMUNE SYSTEM; LEUKOCYTE; NANOTECHNOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

EID: 84877676645     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.48     Document Type: Review

References (91)

1. Leonard F, Talin AA. Electrical contacts to one- and two-dimensional nanomaterials. Nat. Nanotechnol. 6(12), 773-783 (2011).
2. Avouris P, Chen Z, Perebeinos V. Carbon-based electronics. Nat. Nanotechnol. 2(10), 605-615 (2007).
3. Wang L, Li J, Jiang Q, Zhao L. Water-soluble Fe3O4 nanoparticles with high solubility for removal of heavy-metal ions from waste water. Dalton Trans. 41(15), 4544-4551 (2012).
4. Kaittanis C, Santra S, Perez JM. Emerging nanotechnology-based strategies for the identification of microbial pathogenesis. Adv. Drug Deliv. Rev. 62(4-5), 408-423 (2010).
5. Grossman HL, Myers WR, Vreeland VJ et al. Detection of bacteria in suspension by using a superconducting quantum interference device. Proc. Natl Acad. Sci. USA 101(1), 129-134 (2004).
6. Araujo EA, Andrade NJ, da Silva LH et al. Antimicrobial effects of silver nanoparticles against bacterial cells adhered to stainless steel surfaces. J. Food Prot. 75(4), 701-705 (2012).
7. Zou Y, Lee HY, Seo YC, Ahn J. Enhanced antimicrobial activity of nisin-loaded liposomal nanoparticles against foodborne pathogens. J. Food Sci. 77(3), M165-M170 (2012).
8. Costa C, Conte A, Buonocore GG, Del Nobile MA. Antimicrobial silver- montmorillonite nanoparticles to prolong the shelf life of fresh fruit salad. Int. J. Food Microbiol. 148(3), 164-167 (2011).
9. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 8(6), 2101-2141 (2011).
10. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469-478 (2007).
11. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 151(2), 458-465 (2010).
12. Hussain S, Vanoirbeek JA, Hoet PH. Interactions of nanomaterials with the immune system. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(2), 169-183 (2012).
13. Di Gioacchino M, Petrarca C, Lazzarin F et al. Immunotoxicity of nanoparticles. Int. J. Immunopathol. Pharmacol. 24(1 Suppl.), 65S-71S (2011).
14. Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system part II: safety concerns. Nanomedicine (Lond.) (2013) (In Press).
15. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J. Thromb. Haemost. 9(Suppl. 1), 182-188 (2011).
16. Valls Seron M, Haiko J, De Groot PG, Korhonen TK, Meijers JC. Thrombin-activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis. J. Thromb. Haemost. 8(10), 2232-2240 (2010).
17. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J. Thromb. Haemost. 5(Suppl. 1), 24-31 (2007).
18. Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin. Thromb. Hemost. 36(4), 367-377 (2010).
19. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 34(1), 43-62 (2012).
20. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb. Res. 120(Suppl. 2), S137-S140 (2007).
21. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol. Haemost. Thromb. 36(3-4), 122-130 (2008).
22. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 143(7), 819-826 (2004).
23. Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth. Analg. 114(2), 275-285 (2012).
24. Li C, Li J, Li Y et al. Crosstalk between platelets and the immune system: old systems with new discoveries. Adv. Hematol. 2012, 384685 (2012).
25. Rowley JW, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the message. Curr. Opin. Hematol. 19(5), 385-391 (2012).
26. Lee WL, Liles WC. Endothelial activation, dysfunction and permeability during severe infections. Curr. Opin. Hematol. 18(3), 191-196 (2011).
27. Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers 16(Suppl. 1), S11-S21 (2011).
28. Lefkowitz JB. Coagulation pathway and phisiology. In: An Algorithmic Approach to Hemostatic Testing. Kottke-Marchant K (Ed.). CAP Press, IL, USA, 3-12 (2008).
29. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch. Pharm. Res. 32(8), 1103-1108 (2009).
30. Furie B, Furie BC. Mechanisms of thrombus formation. N. Engl. J. Med. 359(9), 938-949 (2008).
31. Hoffman M. Remodeling the blood coagulation cascade. J. Thromb. Thrombolysis 16(1-2), 17-20 (2003).
32. Jackson SP. The growing complexity of platelet aggregation. Blood 109(12), 5087-5095 (2007).
33. Dhadwar SS, Kiernan J, Wen J, Hortelano G. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. J. Thromb. Haemost. 8(12), 2743-2750 (2010).
34. Johnson KA, Zhou ZY. Costs of care in hemophilia and possible implications of health care reform. Hematology Am. Soc. Hematol. Educ. Program. 2011, 413-418 (2011).
35. Zhou ZY, Wu J, Baker J et al. Haemophilia utilization group study - part Va (HUGS Va): design, methods and baseline data. Haemophilia 17(5), 729-736 (2011).
36. Bertram JP, Williams CA, Robinson R, Segal SS, Flynn NT, Lavik EB. Intravenous hemostat: nanotechnology to halt bleeding. Sci. Transl. Med. 1(11), 11ra22 (2009).
37. Beer JH, Springer KT, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 79(1), 117-128 (1992).
38. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: a status report. Semin. Thromb. Hemost. 18(3), 324-332 (1992).
39. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH. Arginyl- glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 70(1), 110-115 (1987).
40. Okamura Y, Fukui Y, Kabata K et al. Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation. Bioconjug. Chem. 20(10), 1958-1965 (2009).
41. Kona S, Dong JF, Liu Y, Tan J, Nguyen KT. Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int. J. Pharm. 423(2), 516-524 (2012).
42. Collins PW. Management of acquired haemophilia A. J. Thromb. Haemost. 9(Suppl. 1), 226-235 (2011).
43. Shafir G, Galperin A, Margel S. Synthesis and characterization of recombinant factor VIIa-conjugated magnetic iron oxide nanoparticles for hemophilia treatment. J. Biomed. Mater. Res. A 91(4), 1056-1064 (2009).
44. Goodnough LT, Shander AS. Recombinant factor VIIa: safety and efficacy. Curr. Opin. Hematol. 14(5), 504-509 (2007).
45. Schutgens RE, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 15(4), 952-958 (2009).
46. Yatuv R, Robinson M, Dayan-Tarshish I, Baru M. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int. J. Nanomedicine 5, 581-591 (2010).
47. Spira J, Plyushch O, Zozulya N et al. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, Phase I/II study. Haemophilia 16(6), 910-918 (2010).
48. Spira J, Plyushch O, Andreeva T et al. Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients. Br. J. Haematol. 158(1), 149-152 (2012).
49. Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J. Thromb. Haemost. 5(5), 901-906 (2007).
50. Bowman K, Sarkar R, Raut S, Leong KW. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J. Control. Release 132(3), 252-259 (2008).
51. Homar M, Cegnar M, Kotnik M, Peternel L. Toward effective long-term prevention of thromboembolism: novel oral anticoagulant delivery systems. Semin. Thromb. Hemost. 36(1), 113-122 (2010).
52. Kemp MM, Linhardt RJ. Heparin-based nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2(1), 77-87 (2010).
53. Loira-Pastoriza C, Sapin-Minet A, Diab R, Grossiord JL, Maincent P. Low molecular weight heparin gels, based on nanoparticles, for topical delivery. Int. J. Pharm. 426(1-2), 256-262 (2012).
54. Jiao Y, Ubrich N, Marchand-Arvier M et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105(2), 230-235 (2002).
55. Jiao YY, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Maincent P. Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles. Drug Deliv. 8(3), 135-141 (2001).
56. Argyo C, Cauda V, Engelke H, Radler J, Bein G, Bein T. Heparin-coated colloidal mesoporous silica nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system. Chemistry 18(2), 428-432 (2012).
57. Tanaka KA, Levy JH. Regulation of thrombin activity - pharmacologic and structural aspects. Hematol. Oncol. Clin. North Am. 21(1), 33-50 (2007).
58. Di Cera E. Thrombin. Mol. Aspects Med. 29(4), 203-254 (2008).
59. Gopinath SC. Anti-coagulant aptamers. Thromb. Res. 122(6), 838-847 (2008).
60. Hsu CL, Chang HT, Chen CT, Wei SC, Shiang YC, Huang CC. Highly efficient control of thrombin activity by multivalent nanoparticles. Chemistry 17(39), 10994-11000 (2011).
61. Shiang YC, Hsu CL, Huang CC, Chang HT. Gold nanoparticles presenting hybridized self-assembled aptamers that exhibit enhanced inhibition of thrombin. Angew. Chem. Int. Ed. Engl. 50(33), 7660-7665 (2011).
62. Kim S, Kunapuli SP. P2Y12 receptor in platelet activation. Platelets 22(1), 54-58 (2011).
63. de Castro S, Maruoka H, Hong K et al. Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2́-deoxyadenosine 3́,5́-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. Bioconjug. Chem. 21(7), 1190-1205 (2010).
64. Kim Y, Hechler B, Klutz AM, Gachet C, Jacobson KA. Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. Bioconjug. Chem. 19(2), 406-411 (2008).
65. Kim Y, Hechler B, Gao ZG, Gachet C, Jacobson KA. PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. Bioconjug. Chem. 20(10), 1888-1898 (2009).
66. Gessi S, Varani K, Merighi S, Ongini E, Borea PA. A(2A) adenosine receptors in human peripheral blood cells. Br. J. Pharmacol. 129(1), 2-11 (2000).
67. Stern ST, Hall JB, Yu LL et al. Translational considerations for cancer nanomedicine. J. Control. Release 146(2), 164-174 (2010).
68. Haller CA, Cui W, Wen J, Robson SC, Chaikof EL. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. J. Vasc. Surg. 43(4), 816-823 (2006).
69. Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J. Biomed. Mater. Res. A 93(3), 1004-1015 (2010).
70. Huang G, Zhou Z, Srinivasan R et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 29(11), 1676-1685 (2008).
71. Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb. Haemost. 93(1), 106-114 (2005).
72. Lowe KC. Second-generation perfluorocarbon emulsion blood substitutes. Artif. Cells Blood Substit. Immobil. Biotechnol. 28(1), 25-38 (2000).
73. Ragaseema VM, Unnikrishnan S, Kalliyana Krishnan V, Krishnan LK. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. Biomaterials 33(11), 3083-3092 (2012).
74. Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 3(6), 1357-1364 (2009).
75. Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin. Drug. Deliv. 5(11), 1185-1198 (2008).
76. Juhlin P, Bostrom PA, Torp A, Bredberg A. Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction. J. Intern. Med. 245(5), 483-488 (1999).
77. Blackwell N, Hollins A, Gilmore G, Norton R. Antistreptokinase antibodies: implications for thrombolysis in a region with endemic streptococcal infection. J. Clin. Pathol. 58(9), 1005-1007 (2005).
78. Heeremans JL, Prevost R, Bekkers ME et al. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb. Haemost. 73(3), 488-494 (1995).
79. Leach JK, O'Rear EA, Patterson E, Miao Y, Johnson AE. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb. Haemost. 90(1), 64-70 (2003).
80. Leach JK, Patterson E, O'Rear EA. Distributed intraclot thrombolysis: mechanism of accelerated thrombolysis with encapsulated plasminogen activators. J. Thromb. Haemost. 2(9), 1548-1555 (2004).
81. Chung TW, Wang SS, Tsai WJ. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co- glycolide) (PLGA) nanoparticles. Biomaterials 29(2), 228-237 (2008).
82. Nguyen PD, O'Rear EA, Johnson AE, Patterson E, Whitsett TL, Bhakta R. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circ. Res. 66(3), 875-878 (1990).
83. Kim IS, Choi HG, Choi HS, Kim BK, Kim CK. Prolonged systemic delivery of streptokinase using liposome. Arch. Pharm. Res. 21(3), 248-252 (1998).
84. Perkins WR, Vaughan DE, Plavin SR et al. Streptokinase entrapment in interdigitation- fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb. Haemost. 77(6), 1174-1178 (1997).
85. Nallamothu R, Wood GC, Kiani MF, Moore BM, Horton FP, Thoma LA. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. PDA J. Pharm. Sci. Technol. 60(3), 144-155 (2006).
86. Nallamothu R, Wood GC, Pattillo CB et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. AAPS PharmSciTech 7(2), E32 (2006).
87. Vaidya B, Agrawal GP, Vyas SP. Platelets directed liposomes for the delivery of streptokinase: development and characterization. Eur. J. Pharm. Sci. 44(5), 589-594 (2011).
88. Nishiya T, Sloan S. Interaction of RGD liposomes with platelets. Biochem. Biophys. Res. Commun. 224(1), 242-245 (1996).
89. Mei H, Shi W, Pang Z et al. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. Biomaterials 31(21), 5619-5626 (2010).
90. Shi W, Mei H, Deng J et al. A tissue factor targeted nanomedical system for thrombi-specific drug delivery. Biomaterials 33(30), 7643-7654 (2012).
91. Marsh JN, Senpan A, Hu G et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond.) 2(4), 533-543 (2007).